PL2772249T3 - Sposób oraz kompozycja do leczenia nadciśnienia wewnątrzgałkowego i jaskry - Google Patents

Sposób oraz kompozycja do leczenia nadciśnienia wewnątrzgałkowego i jaskry

Info

Publication number
PL2772249T3
PL2772249T3 PL14001862T PL14001862T PL2772249T3 PL 2772249 T3 PL2772249 T3 PL 2772249T3 PL 14001862 T PL14001862 T PL 14001862T PL 14001862 T PL14001862 T PL 14001862T PL 2772249 T3 PL2772249 T3 PL 2772249T3
Authority
PL
Poland
Prior art keywords
glaucoma
treatment
composition
intraocular hypertension
intraocular
Prior art date
Application number
PL14001862T
Other languages
English (en)
Inventor
Timo Reunamaki
Pertti Pellinen
Olli Oksala
Kari Lehmussaari
Original Assignee
Santen Pharmaceutical Co Ltd
Agc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2772249(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd, Agc Inc filed Critical Santen Pharmaceutical Co Ltd
Publication of PL2772249T3 publication Critical patent/PL2772249T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL14001862T 2008-05-30 2009-05-28 Sposób oraz kompozycja do leczenia nadciśnienia wewnątrzgałkowego i jaskry PL2772249T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma
EP09754864.8A EP2306977B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma
EP14001862.3A EP2772249B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
PL2772249T3 true PL2772249T3 (pl) 2017-10-31

Family

ID=39940592

Family Applications (4)

Application Number Title Priority Date Filing Date
PL20164602T PL3714877T3 (pl) 2008-05-30 2009-05-28 Sposób i kompozycja do leczenia nadciśnienia wewnątrzgałkowego i jaskry
PL09754864T PL2306977T3 (pl) 2008-05-30 2009-05-28 Sposób oraz kompozycja do leczenia nadciśnienia wewnątrzgałkowego i jaskry
PL17000440T PL3205334T3 (pl) 2008-05-30 2009-05-28 Sposób oraz kompozycja do leczenia nadciśnienia wewnątrzgałkowego i jaskry
PL14001862T PL2772249T3 (pl) 2008-05-30 2009-05-28 Sposób oraz kompozycja do leczenia nadciśnienia wewnątrzgałkowego i jaskry

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL20164602T PL3714877T3 (pl) 2008-05-30 2009-05-28 Sposób i kompozycja do leczenia nadciśnienia wewnątrzgałkowego i jaskry
PL09754864T PL2306977T3 (pl) 2008-05-30 2009-05-28 Sposób oraz kompozycja do leczenia nadciśnienia wewnątrzgałkowego i jaskry
PL17000440T PL3205334T3 (pl) 2008-05-30 2009-05-28 Sposób oraz kompozycja do leczenia nadciśnienia wewnątrzgałkowego i jaskry

Country Status (27)

Country Link
US (3) US9999593B2 (pl)
EP (8) EP2127638A1 (pl)
JP (9) JP2011521943A (pl)
KR (5) KR101820816B1 (pl)
CN (1) CN102083413B (pl)
AR (2) AR071937A1 (pl)
AU (1) AU2009252210C1 (pl)
BR (1) BRPI0913109B8 (pl)
CA (2) CA2965185A1 (pl)
CY (2) CY1115565T1 (pl)
DK (4) DK3205334T3 (pl)
EA (1) EA023661B1 (pl)
ES (6) ES2627837T3 (pl)
GE (1) GEP20156220B (pl)
HR (4) HRP20140979T1 (pl)
HU (3) HUE033103T2 (pl)
JO (1) JO3039B1 (pl)
LT (3) LT2772249T (pl)
MX (1) MX2010012987A (pl)
MY (1) MY159463A (pl)
PL (4) PL3714877T3 (pl)
PT (4) PT2772249T (pl)
SG (1) SG191628A1 (pl)
SI (4) SI3205334T1 (pl)
TW (1) TWI432202B (pl)
UA (1) UA102257C2 (pl)
WO (1) WO2009145356A1 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US10154923B2 (en) * 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
ES2708451T3 (es) * 2010-07-29 2019-04-09 Allergan Inc Soluciones de bimatoprost y timolol sin conservantes
US9061034B2 (en) * 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
AU2011282679A1 (en) * 2010-07-29 2013-03-07 Allergan, Inc. Preservative free bimatoprost solutions
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
EP2618810B1 (en) * 2010-09-21 2016-11-23 S & V Technologies GmbH Cosmetic composition
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
ES2948387T3 (es) 2012-08-24 2023-09-11 Sun Pharmaceutical Ind Ltd Formulación oftálmica de ácidos grasos polioxílicos o lípidos polioxílicos y tratamiento de afecciones oculares
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9913849B2 (en) 2014-01-10 2018-03-13 Manistee Partners Llc Treatment of migraines
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
EP3103439B1 (en) 2015-06-09 2019-08-07 MEDproject Pharma-Entwicklungs- und Vertriebsgesellschaft mbH Drippable ophthalmic bimatoprost gel
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
AU2016349833A1 (en) * 2015-11-06 2018-05-24 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
PT3423076T (pt) 2016-02-29 2024-07-01 Sun Pharmaceutical Ind Ltd Formulações tópicas contendo ciclosporina e respetivas utilizações
GR1009040B (el) * 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
WO2018181294A1 (ja) * 2017-03-27 2018-10-04 興和株式会社 医薬製剤
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
KR102115285B1 (ko) 2017-06-22 2020-05-26 연성정밀화학(주) 녹내장 치료용 점안 조성물
EP4338751B1 (en) * 2017-12-21 2025-09-03 Santen Pharmaceutical Co., Ltd. Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
WO2020013717A1 (en) 2018-07-09 2020-01-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Ophthalmic dispensing device
JP7599838B2 (ja) * 2019-04-10 2024-12-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性医薬組成物
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
CN116687842A (zh) * 2022-02-28 2023-09-05 山东新时代药业有限公司 一种拉坦前列素滴眼液及其制备方法
TW202400133A (zh) * 2022-03-25 2024-01-01 日商坪田實驗室股份有限公司 水性組成物
WO2023241652A1 (zh) * 2022-06-16 2023-12-21 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
WO2024203727A1 (ja) * 2023-03-24 2024-10-03 株式会社坪田ラボ 水性組成物
WO2024232425A1 (ja) * 2023-05-11 2024-11-14 テイカ製薬株式会社 プロスタグランジンＦ２α誘導体の含有率低下が抑制されている製品
JP7757564B1 (ja) 2024-06-28 2025-10-21 東亜薬品株式会社 水性組成物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
EP0286903B2 (en) 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
EP1057486A1 (en) * 1995-11-17 2000-12-06 Alcon Laboratories, Inc. Use of drug combination for treating Glaucoma
ATE221048T1 (de) 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
CA2273837C (en) 1996-12-09 2003-12-30 Bausch & Lomb Incorporated Single-use flexible container
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
ES2265166T3 (es) * 1997-10-13 2007-02-01 R-Tech Ueno, Ltd. Composicion para tratamiento de hipertension intraocular o glaucoma.
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
CA2295512C (en) 1998-07-14 2009-05-26 Alcon Laboratories, Inc. Prostaglandin product
JP2003517441A (ja) * 1998-09-25 2003-05-27 アルコン ラボラトリーズ， インコーポレイテッド 徐放性で快適な眼疾病用組成物および眼疾病の治療方法
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
PL350924A1 (en) 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
KR100791871B1 (ko) 2000-06-19 2008-01-07 산텐 세이야꾸 가부시키가이샤 방부제
JP3876355B2 (ja) 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
EP1321144B1 (en) 2000-09-13 2010-12-08 Santen Pharmaceutical Co., Ltd. Eye drops
TW586946B (en) * 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
AU2003248070A1 (en) 2002-07-16 2004-02-02 Hanshin Yoki Co., Ltd. Chemical container and method of manufacturing the container
EP1547599B1 (en) * 2002-09-09 2017-11-01 Santen Pharmaceutical Co., Ltd. Transparent eye drops containing latanoprost
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
US20060199863A1 (en) * 2003-07-31 2006-09-07 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
US20050287325A1 (en) * 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
US7562796B2 (en) 2004-11-24 2009-07-21 Holopack International Corp. Dispensing container with flow control system
CN102526064A (zh) * 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
ATE555792T1 (de) 2004-12-24 2012-05-15 Santen Pharmaceutical Co Ltd Prostaglandin f2 alpha derivat enthaltende produkte
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US20080269353A1 (en) * 2005-07-13 2008-10-30 Santen Pharmaceutical Co., Ltd. Preventative Composition For Ophthalmic Use
EP1916002B1 (en) 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
DE602006016628D1 (de) 2005-10-10 2010-10-14 Novagali Pharma Sa Prostaglandine enthaltende ophthalmische emulsionen
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
EP2127638A1 (en) 2009-12-02
CY1115565T1 (el) 2017-01-04
SI3714877T1 (sl) 2022-05-31
EA201071413A1 (ru) 2011-06-30
SI2772249T1 (sl) 2017-08-31
EP4289446A2 (en) 2023-12-13
LT3714877T (lt) 2022-04-11
WO2009145356A1 (en) 2009-12-03
CN102083413A (zh) 2011-06-01
KR101650006B1 (ko) 2016-08-22
TW201000104A (en) 2010-01-01
US20180289618A1 (en) 2018-10-11
EP3714877B1 (en) 2022-01-26
EP4289446B1 (en) 2025-02-12
HRP20220361T1 (hr) 2022-05-13
UA102257C2 (uk) 2013-06-25
JP6356868B2 (ja) 2018-07-11
PT3714877T (pt) 2022-03-10
JP2011521943A (ja) 2011-07-28
MY159463A (en) 2017-01-13
EP4035656B1 (en) 2023-11-22
EP2306977A1 (en) 2011-04-13
AR071937A1 (es) 2010-07-28
US20210059931A1 (en) 2021-03-04
JP6148317B2 (ja) 2017-06-14
JP6889789B2 (ja) 2021-06-18
ES2808050T3 (es) 2021-02-25
LT2772249T (lt) 2017-09-11
EP3205334B1 (en) 2020-04-29
AR120961A2 (es) 2022-04-06
AU2009252210C1 (en) 2016-04-14
HUE049923T2 (hu) 2020-11-30
EP4512424A2 (en) 2025-02-26
PL3714877T3 (pl) 2022-05-16
AU2009252210A1 (en) 2009-12-03
AU2009252210B2 (en) 2014-10-16
JP2018154656A (ja) 2018-10-04
KR20160102319A (ko) 2016-08-29
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
JP2020073574A (ja) 2020-05-14
HRP20140979T1 (hr) 2014-11-21
KR102246598B1 (ko) 2021-04-30
KR102114401B1 (ko) 2020-05-25
US10864159B2 (en) 2020-12-15
PL2306977T3 (pl) 2015-01-30
LT3205334T (lt) 2020-09-25
HRP20200998T1 (hr) 2020-10-16
JO3039B1 (ar) 2016-09-05
KR20200057801A (ko) 2020-05-26
JP7265584B2 (ja) 2023-04-26
JP2016065095A (ja) 2016-04-28
ES2907982T3 (es) 2022-04-27
BRPI0913109B1 (pt) 2019-10-22
JP2021120412A (ja) 2021-08-19
HUE058079T2 (hu) 2022-06-28
CN102083413B (zh) 2013-11-06
ES2495316T3 (es) 2014-09-17
US20110152264A1 (en) 2011-06-23
CA2724194A1 (en) 2009-12-03
US9999593B2 (en) 2018-06-19
MX2010012987A (es) 2011-02-24
DK2306977T3 (da) 2014-09-15
PL3205334T3 (pl) 2020-11-02
ES3014089T3 (en) 2025-04-16
KR101988642B1 (ko) 2019-06-12
ES2968837T3 (es) 2024-05-14
EP4035656A1 (en) 2022-08-03
EA023661B1 (ru) 2016-06-30
HUE033103T2 (en) 2017-11-28
SG191628A1 (en) 2013-07-31
CA2965185A1 (en) 2009-12-03
KR20190067272A (ko) 2019-06-14
DK3205334T3 (da) 2020-07-13
EP2772249B1 (en) 2017-05-03
EP4512424A3 (en) 2025-03-05
KR20110011707A (ko) 2011-02-08
CY1120351T1 (el) 2019-07-10
EP2772249A1 (en) 2014-09-03
JP2014133765A (ja) 2014-07-24
EP4289446A3 (en) 2024-01-10
EP4512424B1 (en) 2026-03-18
ES2627837T8 (es) 2018-02-26
DK3714877T3 (da) 2022-02-14
HRP20170769T1 (hr) 2017-08-11
JP6649992B2 (ja) 2020-02-19
JP2023085558A (ja) 2023-06-20
JP2017178957A (ja) 2017-10-05
PT2772249T (pt) 2017-08-08
KR20180008905A (ko) 2018-01-24
DK2772249T3 (en) 2017-07-17
GEP20156220B (en) 2015-01-26
KR101820816B1 (ko) 2018-01-22
EP3205334A1 (en) 2017-08-16
JP7520285B2 (ja) 2024-07-23
JP2024079852A (ja) 2024-06-11
EP2306977B1 (en) 2014-08-13
CA2724194C (en) 2017-06-27
EP3714877A1 (en) 2020-09-30
TWI432202B (zh) 2014-04-01
PT2306977E (pt) 2014-09-22
ES2627837T3 (es) 2017-07-31
BRPI0913109B8 (pt) 2021-05-25
BRPI0913109A2 (pt) 2017-06-20
PT3205334T (pt) 2020-07-31

Similar Documents

Publication Publication Date Title
PL2772249T3 (pl) Sposób oraz kompozycja do leczenia nadciśnienia wewnątrzgałkowego i jaskry
IL251768B (en) Auris formulations for treating otic diseases and conditions
HUE036780T2 (hu) Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
CY2016017I1 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
IL186598A0 (en) Composition and method for the treatment or prevention of glaucoma and ocular hypertension
LT2894165T (lt) Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
EP2326335A4 (en) COMPOSITION FOR A TISSUE PARAMETER IMPLANT AND METHOD OF MANUFACTURING THEREOF
PL2470191T3 (pl) Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
SMT201600080B (it) Inibitori di chinasi janus per il trattamento di occhio secco e altre malattie oculari
SMP200800042B (it) Composizioni e metodi di impiego per anticorpi di dickkopf-1
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
EP2083862A4 (en) COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND DISORDERS
PL1881823T3 (pl) Kompozycje i sposoby leczenia chorób oczu
PL2234621T3 (pl) Kompozycje i sposoby leczenia chorób paznokcia
IL207397A0 (en) Difluorobiphenylamide derivtives for the treatment of ocular hypertension
EP2254857A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES
IT1398378B1 (it) Citicolina per il trattamento del glaucoma e dell'ipertensione oculare.
IL209947A0 (en) Compositions and methods for treating corneal inflammation
BRPI0918108A2 (pt) composição para tratamento, método de tratamento e uso de uma composição
EE05592B1 (et) Alumiiniumšlaki mbert””tlemise meetod
BRPI0918361A2 (pt) composição para tratamento, método de tratamento e uso de uma composição
BRPI0907329A2 (pt) composição e método de gesso de não hidratação
IL205774A0 (en) Novel compounds for the treatment of glaucoma and ocular hypertension
IL197323A0 (en) Novel method and compositions for prevention or treatment of glaucoma and ocular hypertension
TH0801005183A (th) องค์ประกอบและวิธีการของการใช้สำหรับแอนติบอดีต้านสเคลอรอสติน